Nipro Corp. (TYO:8086) and NeuroMetrix Inc. (NSDQ:NURO) announced a collaboration to market NeuroMetrix’s NC-stat diagnostic nerve testing device.
The NC-stat test is a quantitative point-of-care test that evaluates systemic neuropathies like diabetic peripheral neuropathy, a common disease affecting more than half of diabetics which may lead to foot ulcers and limb amputation.
This may be the boost that Neurometrix needs as it continues to shore up its flagging stock price. The company asked shareholders to approve a reverse stock split to boost its share price in April.
MedCity News Pivot Podcast: How Emergency Departments Are Using Real-Time Data to Improve Outcomes
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
The companies plan to launch during the annual conference of the American Diabetes Association late in June, according to the release.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.